Update on clinical gene therapy in childhood

Archives of Disease in Childhood

Volumn 92, Issue 11, 2007, Pages 1028-1031

  Qasim, Waseem ^a   Gaspar, H Bobby ^a   Thrasher, Adrian J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR;

BLOOD DISEASE; COMBINED IMMUNODEFICIENCY; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPATHOLOGY; LEUKEMOGENESIS; LONG TERMINAL REPEAT; LYMPHOCYTOPENIA; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

ADENOSINE DEAMINASE; CHILD; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RETROVIRIDAE; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 35748979682     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.108787     Document Type: Review

References (30)

1. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet 2001;357:1863-9.
2. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003;361:553-60.
3. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999;340:508-16.
4. Hirschhorn R, Yang DR, Puck JM, et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet 1996;13:290-5.
5. Bousso P, Wahn V, Douagi I, et al. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc Natl Acad Sci U S A 2000;97:274-8.
6. Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110:521-9.
7. Wu X, Li Y, Crise B, et al. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003;300:1749-51.
8. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-72.
9. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linlced severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004;364:2181-7.
10. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-93.
11. Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Abina S, et al. Gene therapy for severe combined immunodeficiency. Annu Rev Med 2005;56:585-602.
12. Thrasher AJ, Hocein-Bey-Abina S, Caspar HB, et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005;105:4255-7.
13. Bloese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995;270:475-80.
14. Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial Blood 2003;101:2563-9.
15. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995;270:470-5.
16. Hoogerbrugge PM, van Beusechem VW, Fischer A, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 1996;3:179-83.
17. Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 1998;4:775-80.
18. Aiuti A, Vai S, Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 2002;8:423-5.
19. Engel BC, Podsakoff GM, Ireland JL, et al. Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism - a case report. Blood 2007;109(2):503-6.
20. Aiufi A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-13.
21. Caspar HB, Biorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SOD by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 2006;14:505-13.
22. Hocein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-6.
23. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-19.
24. Woods NB, Bottero V, Schmidt M, et al. Gene therapy: therapeutic gene causing lymphoma. Nature 2006;440:1123.
25. Thrasher AJ, Gaspar HB, Baum C, et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 2006;443:E5-6.
26. Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006;108:2545-53.
27. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulornatous disease by gene therapy, augmented by 'insertional activation of MDS1-EV11, PRDM16 or SETBP1. Nat Med 2006,12:401-9.
28. Kelly PF, Radtke S, Kalle C, et al. Stem cell collection and gene transfer in Fanconi anemia. Mol Ther 2007;15:211-19.
29. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 2006;103:17372-7.
30. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.